RecruitingPhase 1NCT06963346

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

12 participants

Start Date

Jun 24, 2025

Study Type

INTERVENTIONAL

Conditions

Bladder Cancer

Summary

In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Durvalumab and a drug called Romidepsin for people with bladder cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.